Meeting
2020 Gastrointestinal Cancers Symposium
The antidiarrheal efficacy of a proprietary amino acid mixture (enterade) in neuroendocrine tumor (NET) patients: Updated data.
Authors
Aman Chauhan
University of Kentucky, Division of Medical Oncology, Lexington, KY
Aman Chauhan , Rachel C. Miller , Laura Luque , Heidi Weiss , Lowell Brian Anthony
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer
Track
Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Pancreatic Cancer,Small Bowel Cancer,Other GI Cancer
Sub Track
Symptoms, Toxicities, and Whole-Person Care
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 614)
Abstract #
614
Poster Bd #
F17
Abstract Disclosures
Similar Posters
Poster
2018 Palliative and Supportive Care in Oncology Symposium
The antidiarrheal efficacy of a proprietary amino acid mixture in neuroendocrine tumor (NET) patients.
First Author: Laura Luque
Poster
2018 Gastrointestinal Cancers Symposium
The antidiarrheal efficacy of a proprietary amino acid mixture in gastroenteropancreatic neuroendocrine patients.
First Author: Aman Chauhan
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of LY3537982, a potent and highly selective KRAS G12C inhibitor in KRAS G12C-mutant GI cancers: Results from a phase 1 study.
First Author: Antoine Hollebecque
Poster
2023 ASCO Gastrointestinal Cancers Symposium
ETCTN 10450: A phase I trial of peposertib and lutetium 177 DOTATATE in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
First Author: Aman Chauhan